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ABSTRACT 
Objective: The objective of this research was to develop a simple, rapid and sensitive liquid chromatography/tandem mass spectrometry (LC-
MS/MS) method for the simultaneous quantification of artesunate and amodiaquine in human plasma. 
Methods: An analytical method based on LC-MS/MS has been developed and validated for the simultaneous determination of artesunate and 
amodiaquine in human plasma. Isotope-labeled compounds are used as internal standards for the quantification of these drugs. Analytes were 
extracted from the plasma using solid phase extraction (SPE) technique and chromatographed on a C8 column using an isocratic mobile phase 
composed of 0.1% ammonia solution and methanol (10:90, v/v). The mobile phase was pumped at a flow rate of 1.00 ml/min. A total of five 
analytical batches were generated for the calculation of intra-day and inter-day precision and accuracy during the entire course of validation. 
Results: The assay exhibits excellent linearity in the concentration range of 3.07–305.29 ng/ml for artesunate and 0.30–30.01 ng/ml for 
amodiaquine. Intra-day and inter-day precision and accuracy results are well within the acceptance limits. All the stability experiments were 
conducted in plasma samples and in neat samples are complying with the recent US FDA and EMEA guidelines.  
Conclusion: The proposed LC–MS/MS assay method is simple, rapid and sensitive enough for the simultaneous determination of artesunate and 
amodiaquine in human plasma. This method was successfully used to quantitate the in-vivo plasma concentrations obtained from a pharmacokinetic 
study and the results were validated by conducting incurred samples reanalysis (ISR). 
Keywords: Artesunate and amodiaquine, Human plasma, LC–MS/MS, Method validation, Pharmacokinetics. 
 
INTRODUCTION 
Malaria is one of the most important infectious diseases in the 
world, causing hundreds of millions of illnesses and an estimated 1 
million deaths each year. The disease is caused by P. falciparum. 
Many drugs are available for the treatment of uncomplicated 
malaria. The most important new class of antimalarial agents is the 
artemisinin. The World Health Organization (WHO) recently 
recommended the use of artemisinin-based combination therapy 
(ACT) for the treatment of uncomplicated P. falciparum malaria [1]. 
Artesunate (AS) is a water-soluble semi-synthetic derivative of 
artemisinin and can be given by injection [2]. Amodiaquine (AQ) is a 
4-aminoquinoline compound similar to chloroquine, is also used as 
an antimalarial agent. A combination of AS and AQ is indicated for 
the treatment of uncomplicated cases of malaria due to P. falciparum 
strains which are susceptible to AQ as well as to AS [3]. AS/AQ 
combination for uncomplicated malaria is efficacious and safe in 
children also [4, 5]. This combination is drawing a certain degree of 
interest due to their half-life. AS is having a short half-life, whereas, 
AQ has a long half. The short half-life drug achieves substantial and 
rapid parasite killing while a high concentration of the long half-life 
drug kills off the remaining malaria parasites [6, 7]. 
As per the literature survey, many LC-MS/MS methods [8-17] have 
been reported for the determination of AS individually or along with 
its metabolite in a variety of biological samples. Similarly, one LC-
MS/MS method [17] and one ion-pair liquid chromatography–
tandem mass spectrometry method [18] has been reported for the 
determination of AQ along with its metabolite in biological samples. 
It is essential to develop a bioanalytical method suitable for 
simultaneous determination of AS and AQ in human plasma, a fixed 
dose combination (FDCs) is available in the market. These methods 
are helpful to examine the tolerability and safety profile of FDCs 
and/or for comparative bioavailability and bioequivalence studies. 
Also, analysis of FDCs in a single run reduces the experimental cost. 
To our knowledge, one high-performance liquid chromatography 
with electrochemical detection method [19] and one LC-MS/MS 
method [20] have been reported for the simultaneous determination 
of AS and AQ in human plasma. The conventional HPLC methods 
must sacrifice time, resolution or sensitivity [19].  
Also, reported LC-MS/MS method is having limitations like gradient 
mobile phase composition, lack of specificity due to the improper 
characterization of more number of analytes in a single run, less 
sensitivity and longer chromatographic run time. In view of the 
above, the authors have attempted to develop a simple, specific, 
sensitive and rapid LC-MS/MS method for simultaneous 
determination of AS and AQ in human plasma using artesunate d4 
(IS1) and amodiaquine d10 (IS2) as internal standards, respectively. 
The advantages of the proposed method over reported procedures 
in terms of specificity, selectivity, use of solid–phase extraction 
(SPE) technique without drying, evaporation and reconstitution 
steps, minimum usage of organic solvents, employed very low 
plasma volume (100 µl) and rapid with the chromatographic run 
time of 4 min which makes the method high throughput. Use of 
deuterated compounds as internal standards minimizes matrix 
effect related problems and variability in recovery between the 
analyte and the IS [21]. The method ensured the estimation of AS 
and AQ in real time samples collected from healthy male subjects up 
to 48 h of post dosing with desired accuracy and precision to 
support a pharmacokinetic study in healthy volunteers. The ISR 
results obtained demonstrated that the present method is highly 
reproducibility and suitable for the pharmacokinetic/bioequivalence 
studies in humans. 
MATERIALS AND METHODS 
Materials and reagents 
The reference sample of AS (98.01%) and amodiaquine 
hydrochloride (91.56%), were obtained from Mangalam Drugs and 
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Organics Limited, India, whereas IS1 (100%) and IS2 (100%) were 
purchased from Vivan Life Sciences Private Limited, India. All the 
solvents used in the study are LC-MS grade. Methanol used as an 
organic modifier and purchased from J. T Baker (Phillipsburg, USA). 
Analytical grade ammonia and ammonium acetate were purchased 
from Merck, (Mumbai, India). Ultra-pure water was prepared at our 
laboratory using Milli Q water purification system procured from 
Millipore (Bangalore, India). Human blank plasma was obtained 
from Deccan’s Pathological Labs, (Hyderabad, India). 
LC–MS/MS instrument and conditions  
An HPLC system (Shimadzu Corporations, Kyoto, Japan) coupled 
with AB Sciex API–4000 mass spectrometer (Foster City, CA, USA) 
was used for the study. A 15 µl aliquot of processed samples were 
injected into the analytical column (Kromasil C8, 150 * 4.6 mm, 5 µm; 
Make: Akzo Noel) along with an isocratic mobile phase composed of 
0.1% ammonia solution and methanol and (10:90, v/v). The mobile 
phase was pumped at a flow rate of 1.00 ml/min with splitter 
(50:50). The detailed mass spectrometric conditions and 
quantification parameters are listed in the table 1. 
Preparation of calibration curve standards and quality control 
samples 
Two separate stock solutions (1 mg/ml) of AS and AQ were 
prepared in HPLC grade methanol and used for the preparation of 
calibration curve (CC) standards and quality control (QC) samples. 
Further dilutions were made in a mixture of methanol and water 
(50:50, v/v; diluent). Likewise, IS1 and IS2 stock solutions (1 
mg/ml) were prepared in methanol separately. A combined working 
solution for IS1 (1000 ng/ml) and IS2 (200 ng/ml) was also 
prepared in diluent. All the stock solutions were found to be stable 
for 21 d at 2–8 °C in refrigerator. An aliquot of 50 µl combined 
working standard dilution of AS and AQ was spiked into 950 µl of 
screened human plasma to obtain calibration standards and quality 
control samples. Calibrates were prepared at a concentrations of 
3.07, 6.14, 15.34, 30.68, 61.36, 122.73, 183.17, 244.23 and 305.29 
ng/ml for AS and 0.30, 0.60, 1.51, 3.02, 6.03, 12.06, 18.01, 24.01 and 
30.01 ng/ml for AQ. The QC samples were prepared at five different 
concentration levels of 3.11 (lower limit of quantification, LLOQ), 
9.21 (low quality control, LQC), 46.03 (middle quality control, MQC–
1), 152.93 (MQC–2) and 255.74 (high quality control, HQC) ng/ml 
for AS and 0.31 (LLOQ), 0.91 (LQC), 4.53 (MQC–1), 15.04 (MQC–2) 
and 25.14 (HQC) ng/ml for AQ. All the prepared plasma samples 
were stored at–70±10 °C. 
Sample extraction protocol 
All frozen samples were thawed at room temperature and vortexed 
to ensure complete mixing of the contents. A 100 µl aliquot of 
plasma sample was pipetted into pre-labelled polypropylene tubes. 
Then 20 µl of internal standard working solution (a combined 
dilution of IS1 and IS2 at a concentration of 1000 ng/ml and 200 
ng/ml, respectively) was added to it and vortexed for 10 s. To this, 
200 µl of 100 mM ammonium acetate was added and vortex.  
The sample mixture was loaded onto a Strata-X 33 µm polymeric 
sorbent (30 mg/1 ml) cartridge that was preconditioned with 1.0 ml 
of methanol followed by 1.0 ml of water and 1.0 ml of 100 mM 
ammonium acetate buffer. After applying the maximum pressure, 
the extraction cartridge was washed with 1.0 ml 100 mM 
ammonium acetate buffer followed by 2 ml of HPLC grade water (1.0 
ml of each time). Analytes and the internal standards were eluted 
with 1.0 ml of mobile phase. Aliquot of 15 μL of the extract was 
injected into the chromatographic system. 
  
Table 1: Tandem mass spectrometer main working parameters 
Parameter Analyte 
AS AQ IS1 IS2 
Mode of analysis Positive Positive Positive Positive 
Ion transition, m/z 402.3/267.3 356.3/283.1 406.3/267.3 366.2/283.1 
Source temperature, °C 550 550 550 550 
Dwell time per transition, msec 200 200 200 200 
Nebulizer gas, psi 50 50 50 50 
TurboIon gas, psi 30 30 30 30 
Curtain gas, psi 30 30 30 30 
Collision gas, psi 4 4 4 4 
Ion spray voltage, V 5500 5500 5500 5500 
Entrance potential, V 10 10 10 10 
Declustering potential, V 36 35 36 35 
Collision energy, V 15 25 15 25 
Collision cell exit potential, V 15 15 15 15 
Resolution Unit Unit Unit Unit 
 
Method validation 
A complete and through validation was carried out as per US FDA 
[22] and EMEA guidelines [23]. The validation parameters tested are 
system suitability, carryover test, selectivity, specificity, sensitivity, 
matrix effect, linearity, precision and accuracy, recovery, dilution 
integrity, stability, run size evaluation and method ruggedness.  
Pharmacokinetic study protocol 
A pharmacokinetic study was conducted in healthy male subjects (n 
= 7) under fasting condition using fixed dose combination (100/270 
mg) of AS and AQ. The study was approved by the Independent 
Ethics Committee (Reg. No: ECR/70/Indt/AP2013) and conducted 
as per the GCP regulations. The subjects with an age group of 20–40 
y and body–mass index (BMI) of ≥18.5 kg/m2 and ≤24.9 kg/m2, with 
body weight not less than 50 kg were selected for the study. All the 
subjects were fastened for 12 h before administration of the tablet 
formulation and kept in-house for 24 h during the study. Drinking 
water is restricted for one hour before and after dosing. Post-dosing, 
a standard meal is provided at specified intervals. Blood samples 
were collected at 0.083, 0.167, 0.25, 0.333, 0.5, 0.667, 0.833, 1, 1.25, 
1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 h of post dose 
in K2 EDTA vacutainer (5 ml) collection tubes (BD, Franklin, NJ, 
USA). A predose sample was also collected from each subject to 
check the possible interferences. The blood samples were 
centrifuged at 3200 rpm for 10 min and the plasma was collected 
and stored at–70±10 °C till their use. The pharmacokinetic 
parameters of AS and AQ are calculated by using Win Nonlin 
software (Version 5.2). Non–compartmental model was employed 
for the preset study. The study data was validated through ISR. For 
ISR, a total of 14 samples (two samples from each subject) were 
selected for each analyte near to Cmax and the elimination phase. The 
percent change deviation between initial and ISR value allowed 
is±20% [24, 25]. 
RESULTS AND DISCUSSION 
Mass spectrometry 
The purpose of the study was to develop and validate a LC-MS/MS 
method for the simultaneous determination AS and AQ in human 
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plasma suitable for the pharmacokinetic and bioavailability or 
bioequivalence. Analysis of multiple analytes in a single run 
considerably reduces the researchers’ time and experimental cost. 
Hence, rapid, specific and sensitive methods like liquid 
chromatography coupled with mass spectrometry are required to 
analyze the drug candidates in biological samples. Mass 
spectrometric conditions were optimized in positive and negative 
ionization modes using tuning solution. The high-intensity response 
was obtained in positive mode than the negative mode for AQ and 
the IS2. But the intensity response obtained for the AS and IS1 was 
very low and not enough to quantify. Hence, ammonia solution was 
added to a stock solution of AS and IS1 (0.3 ml in 10 ml) to produce 
ammonium adduct (M+NH4)+ and the same was detected. Compound 
parameters like declustering potential (DP), collision energy (CE) 
and collision cell exit potential (CXP) were optimized to obtain most 
intense and consistent production Q3 MS spectra of analytes and the 
internal standards. The source parameters like nebulizer gas (GS1), 
auxiliary gas (GS2), collision gas (CAD), temperature and ion spray 
voltage were optimized to obtain an adequate and reproducible 
response. Detection of the ions was carried out in the multiple 
reaction monitoring (MRM) mode by monitoring the transition pairs 
of m/z 402.3 (M+NH4)+ precursor ion to the m/z 267.3 for AS, m/z 
356.3 precursor ion to the m/z 283.1 for AQ, m/z 406.3 
(M+NH4)+precursor ion to the m/z 267.3 for IS1 and m/z 366.2 
precursor ion to the m/z 283.1 production for the IS2. The dwell 
time for each transition was set at 200 ms. multiple reactions 
monitoring (MRM) was chosen for the present assay development as 
this technique provides inherent selectivity and sensitivity for 
pharmacokinetic studies [26]. 
Chromatographic conditions 
The critical chromatographic conditions such as mobile phase 
composition, flow rate, column type and injection volume were 
carefully monitored to obtain the good resolution from the 
endogenous components and to give better sensitivity with short 
run time. The composition of the mobile phase was elevated with 
acetonitrile and methanol by varying its proportion with volatile 
buffers like ammonium formate, ammonium acetate, as well as basic 
additives like ammonia solution in varying strength. Finally, the 
promising results were archived with an isocratic mobile phase 
composed of 0.1% ammonia solution in water and methanol (10:90, 
v/v) as gave symmetric peak shape, better separation and best 
sensitivity for the analytes. Among the various chromatographic 
columns (Kromasil C8; Hypurity advance; Zorbax SB C18; Kromasil 
100–5C18; Ace 3 C18; Alltima HP C18; Zorbax XDB–phenyl; Discovery 
HS C18) tested for their suitability Kromasil C8, 150 × 4.6 mm, 5 µm 
column gave good peak shape and response even at lowest 
concentration level for both the analytes. The mobile phase flow rate 
was set at 1.0 ml/min allowing a run time of 4 min. 
Optimization of extraction procedure 
The reported procedures have employed protein precipitation (PP) 
[12, 18, 20], liquid-liquid extraction (LLE) [8, 13, 15] and SPE [9, 10, 
16, 17, 19] with drying evaporation and reconstitution steps to 
extract AS and AQ from biological samples. PP is most likely to cause 
ion suppression, since this method fails to remove sufficiently 
endogenous compounds such as lipids, phospholipids, fatty acids, 
etc. Similarly, LLE requires more organic solvent for extraction 
causes environmental hazards due to inhalation of the non-polar 
organic solvents. SPE is the most popular sample preparation 
technique due to following advantages: high recovery, effective 
sample preparation, required less organic solvent compared to LLE, 
ease of operation and a greater possibility of automation. Also, SPE 
technique gives clear extracts than the PP and LLE hence the 
influence on sensitivity is significantly less. Hence, SPE was tested 
with Bond Elut Plexa, Oasis HLB, and Orpheus C18 extraction 
cartridges with/without acidic buffer addition to obtaining the clean 
sample without any interference. Among the various extraction 
cartridges tested, promising results were obtained with Strata–X 33 
µm polymeric sorbent cartridge gave superior recovery for the 
analytes compared with PP and LLE. Use of ammonium acetate 
buffer (100 mM) as an extraction helped in achieving reproducible 
and highest recoveries for both the analytes. Also, ammonium 
acetate buffer used as a washing solvent during SPE procedure to 
eliminate the possible interference. Use of mobile phase as an 
eluting solvent helped in achieving reproducible and quantitative 
recovery for the analyte devoid of drying and reconstitution steps. 
Internal standard selection 
Internal standard selection is an important aspect to achieve 
acceptable method performance, especially with LC-MS/MS, where 
matrix effects can lead to poor analytical results [27]. Deuterated 
standards of the analyte as an internal standard are helpful to obtain 
increased precision and accuracy results in bioanalysis where 
significant matrix effect is possible. Also, limit the recovery variation 
between the analyte and internal standard. Hence, deuterated 
standards of AS and AQ such as artesunate d4 and amodiaquine d10 
are used as internal standards, respectively and were found to be 
best for the present purpose. 
System suitability  
System suitability test was performed before the start of everyday 
analysis. A mixture of a neat sample containing analytes at middle 
QC concentration and internals standards at working concentration 
were injected for the system suitability experiment. The precision of 
system suitability test is within the acceptance limits during the 
entire method validation. The precision (% CV) for system suitability 
test was found to be less than 1% for retention time and 1.3 % for 
area ratio of AQ and AS.  
Selectivity and chromatography 
Selectivity of the proposed method was evaluated by using 6 control 
human plasma lots (4 were normal and one lipemic and one 
haemolyzed). Each lot was analyzed as blanks and after spiking the 
plasma with the analyte at the LLOQ for any interference. The degree 
of interference by endogenous plasma constituents with the analytes 
and IS was assessed by inspection of chromatograms derived from 
processed blank plasma sample. As shown in Figs. 1A & 2A, no 
significant direct interference in the blank plasma traces was observed 
from endogenous substances in drug–free plasma at the retention time 
of the analytes. fig. 1B and 2B depicts an LLOQ sample of AS and AQ 
along with the respective internal standards. Similarly, no interference 
was observed from commonly used medications such as 
acetaminophen, diphenhydramine, pantoprazole, nicotine, ibuprofen, 
caffeine and pseudoephedrine. No effects of cross-talk were observed. 
Fig. 3 and 4 depicts a representative chromatogram of AQ and AS 
resulting from the analysis of subject blank plasma sample along with 
the respective IS and 0.333 h subject plasma sample after the single 
oral dose of a AQ (100 mg) and AS (270 mg) tablet. 
Sensitivity 
Analyte sensitivity (lowest limit of reliable quantification; LLOQ) 
was determined at the concentration of 3.07 ng/ml for AS and 0.30 
ng/ml for AQ. At this concentration, the precision and accuracy 
results of AS were found to be 3.12% and 95.09%. Similarly, the 
precision and accuracy results of AQ were found to 3.24% and 
102.48%. The signal–to–noise ratio (S/N) was measured at LLOQ 
concentration and found to be ≥10 for both the analytes.  
Matrix effect 
Sample preparation with SPE procedure found free from significant 
matrix effect. This experiment was done with the aim to check the 
effect of six lots of plasma on the back calculated value of QC's 
nominal concentration. The precision and accuracy for AS at LQC 
concentration were found to be 1.62% and 94.88%, and at HQC level 
they were 3.09% and 99.01%, respectively. Similarly, the precision 
and accuracy for AQ at LQC concentration were found to be 3.50% 
and 92.14%, and at HQC level they were 3.85% and 101.49%, 
respectively. No significant matrix effect was observed in all the six 
batches of human plasma for the analyte at low and high-quality 
control concentrations.  
Calibration curve and linearity 
Nine–point calibration curve was found to be linear over the 
concentration range of 3.07–305.29 ng/ml for AS and 0.30–30.01 
ng/ml for AQ. After comparing the two weighting models (1/x and 
Makula et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 12, 105-112 
108 
1/x2), a regression equation with a weighting factor of 1/x2 of the 
drug to the IS concentration was found to produce the best fit for the 
concentration–response detector relationship for both the analytes 
in human plasma. The mean correlation coefficient of the weighted 
calibration curves generated during the validation was ≥ 0.99 for 
both the analytes. 
Precision and accuracy 
Intra-day precision and accuracy results were calculate using two 
different batches analyzed on a single day, whereas inter-day results 
were calculated using five different batches analyzed on a three 
successive day. The overall results are summarized in table 2. 
 
 
Fig. 1: Typical MRM chromatograms of AS (left panel) and the IS1 (right panel) in human blank plasma (A) and a LLOQ sample along with IS1 (B) 
 
 
Fig. 2: Typical MRM chromatograms of AQ (left panel) and the IS2 (right panel) in human blank plasma (A) and a LLOQ sample along with IS2 (B) 
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Fig. 3: Typical MRM chromatograms of a 0.333 h plasma sample (294.88 ng/ml) showing AS peak along with IS1 obtained following oral 
administration of 100 mg AS tablet to a healthy volunteer 
 
 
Fig. 4: Typical MRM chromatograms of a 0.333 h plasma sample (10.96 ng/ml) showing AQ peak along with IS2 obtained following oral 
administration of 270 mg AS tablet to a healthy volunteer 
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Table 2: Intra–day and inter–day precision and accuracy data for AS and AQ 
QC Intra–day precision and accuracy (n=12; 6 from 
each batch) 
























































































The recoveries of analytes and the internal standards with SPE 
procedure were good and reproducible. Recovery of the analytes 
was determined at three concentration levels i.e. LQC, MQC2 and 
HQC. The overall mean recovery (with the precision range) of AS 
was found to be 92.20 ± 1.05% (4.21–7.69%), whereas for AQ was 
88.94 ± 4.44% (3.57–6.16%). Similarly, the recovery (with the 
precision range) of the IS1 and IS2 were 92.57% (5.06–7.83%) and 
85.21% (5.24–8.67%), respectively. 
Dilution integrity 
Dilution integrity experiment was conducted to extend the upper 
limit of quantification suitable for higher dose of AS and AQ. Dilution 
integrity test was performed using a concentration of 508.81 ng/ml 
for AS and 50.02 ng/ml for AQ. The precision and accuracy for AS at 
1/2 dilution were found to be 1.39% and 97.44%, and at 1/4 
dilution they were 2.00% and 101.39%, respectively. Similarly, the 
precision and accuracy for AQ at LQC concentration were found to 
be 5.10% and 102.85%, and at HQC level they were 5.91% and 
105.43%, respectively. 
Stability studies 
Stability of analytes in human plasma samples and stability of 
processed samples was evaluated under different conditions. A wide 
range stability experiments namely auto–sampler stability (75 h), 
repeated freeze–thaw cycles (4 cycles), bench top stability (13 h), 
reinjection stability (52 h), wet extract stability (72 h at 2–8 °C) and 
long–term stability at–20 °C &–70 °C for 87 d had been performed 
throughout validation. The mean % nominal values were found to be 
within ±15% of the predicted concentrations for the analyte at their 
LQC and HQC levels and the precision (% CV) values were within 
15% (table 3). All the stability study results were well within the 
specified limits over the total validation. 
 
Table 3: Stability samples result for AS and AQ (n=6) 
Analyte Stability test QC (spiked concentration  (ng/ml) Mean ± SD (ng/ml) Accuracy/ Stability (%) Precision (%) 
AS Processa 9.21 8.48 ± 0.89 92.16 10.48 
  255.74 251.83± 9.75 98.47 3.87 
 Processb 9.21 9.22 ± 0.66 100.11 7.11 
  255.74 234.71 ± 3.16 91.78 1.35 
 Bench topc 9.21 10.01 ± 0.36 108.70 3.60 
  255.74 253.95 ± 8.47 99.30 3.34 
 FTd 9.21 9.14 ± 0.43 99.23 4.68 
  255.74 235.61 ± 8.07 92.13 3.43 
 Reinjectione 9.21 10.01 ± 0.36 108.76 3.60 
  255.74 256.37 ± 2.82 100.25 1.10 
 Long–termf 9.21 8.78 ± 0.50 95.37 5.66 
  255.74 246.15 ± 9.98 96.25 4.05 
AQ Processa 0.91 0.93 ± 0.02 102.30 2.31 
  25.14 25.23 ± 0.12 100.34 0.47 
 Processb 0.91 0.80 ± 0.02 88.20 2.63 
  25.14 22.78 ± 0.26 90.59 1.15 
 Bench topc 0.91 0.82 ± 0.03 90.96 3.40 
  25.14 22.73 ± 0.34 90.38 1.49 
 FTd 0.91 0.82 ± 0.02 90.26 2.10 
  25.14 22.70 ± 0.36 90.30 1.60 
 Reinjectione 0.91 0.85 ± 0.04 93.66 4.19 
  25.14 25.60 ± 1.14 101.82 4.47 
 Long–termf 0.91 0.88 ± 0.07 97.46 8.11 
  25.14 24.49 ± 0.55 97.39 2.25 
a after 75 h in autosampler at 10°C; b after 72 h in refrigerator at 2–8°C; c after 13 h at room temperature; d after 4 freeze and thaw cycles; e after 52 h 
of Reinjection; f at–70°C for 87 d Stock solutions of AS, AQ, IS1 and IS2 were found to be stable for 28 d in refrigerator at 2–8 °C. The percentage 
stability (with the precision range) of AS, AQ, IS1 and IS2 was 99.64% (1.02–3.39%), 102.79% (0.96–1.55%), 99.34% (2.25–2.86%) and 97.92% 
(1.99–4.65%), respectively.  
 
Long run evaluation 
Long run evaluation experiment was carried out to assess the total 
number of the samples can be analyzed in a single run. A batch size 
of 195 samples containing 40 sets each of LQC, MQC1, MQC2 and 
HQC (samples stored at–70 °C) and 24 freshly spikes QC samples (6 
sets at each level) were analyzed for the long run evaluation. These 
quality control samples were quantified by using a freshly spiked 
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calibration curve standards. For AS, 160 QC’s out of 160 QC’s of 
stored QC’s and 24 QC’s out of 24 QC’s of freshly prepared QCs were 
within 15% of their respective nominal (theoretical) values. 
Similarly, 149 QC’s out of 160 QC’s of stored QC’s and 23 QC’s out of 
24 QC’s of freshly prepared QCs for AQ were within 15% of their 
respective nominal (theoretical) values. 
Ruggedness 
The ruggedness of the method was established by analyzing one 
precision and accuracy batch on the different instrument of the 
same make. Also, the precision and accuracy batch was processed 
by the analyst who was not involved in the study. The precision 
(%CV) and accuracy values for AS were ranged from 1.57–10.68% 
and 93.78–103.59%, respectively. The precision (%CV) and 
accuracy values for AQ were ranged from 1.14–7.12% and 88.59–
109.04%, respectively. 
Pharmacokinetic study results 
The validated method was then tested for its applicability to a 
pharmacokinetic study in 7 healthy male subjects. The obtained 
pharmacokinetic results were listed in table 4. The mean plasma 
concentration vs time profile of AS and AQ are displayed in fig. 5 
(presented up to 10 h in order to depict the plot with better 
clarity). 
 
Table 4: Pharmacokinetic parameters of AS and AQ (n=6, 
mean±SD) 
Parameter AS AQ 
Cmax (ng/ml) 222.10±48.61 11.90±2.25 
tmax (h) 0.26±0.06 0.83±0.33 
AUC0–t (ng h/ml) 88.25±30.24 70.05±3.68 
AUC0–inf (ng h/ml) 92.21±30.88 79.56±6.23 
t1/2 (h) 0.48±0.21 15.44±5.80 
Kel (h–1) 1.71 ± 0.74 0.05 ± 0.02 
Incurred sample reanalysis 
Currently, US FDA introduced the importance of incurred sample 
reanalysis (ISR) to authenticate the study data. A total of 14 samples 
for each analyte were evaluated for ISR. The differences in 
concentrations between the ISR and the initial values for all the 
tested samples were less than 15% (table 5), indicating good 
reproducibility of the present method. 
 
Fig. 5: Mean plasma concentration–time profile of AS (A) and AQ 
(B), in human plasma following oral dosing of AS (100 mg) and 
AQ (270 mg) tablet to healthy volunteers (n = 7) 
 




















1 0.167 150.78 141.21 6.55 0.667 14.216 13.621 4.27 
1 2 10.50 9.62 8.66 24 1.096 0.991 10.06 
2 0.25 177.72 160.29 10.32 0.333 10.964 11.970 -8.77 
2 1.75 13.51 13.92 -3.01 16 1.003 1.124 -11.38 
3 0.25 194.76 175.70 10.29 0.833 6.404 6.838 -6.55 
3 0.833 11.60 10.90 6.21 12 1.299 1.205 7.51 
4 0.167 133.40 139.88 -4.74 0.5 8.438 8.134 3.67 
4 1 10.69 10.90 -1.94 24 1.012 0.991 2.10 
5 0.167 202.89 199.23 1.82 0.333 5.255 5.358 -1.94 
5 1 11.86 12.32 -3.82 10 1.524 1.644 -7.58 
6 0.333 193.59 214.31 -10.16 0.833 8.335 8.228 1.29 
6 1.5 11.83 10.59 11.08 20 1.045 1.120 -6.93 
7 0.25 106.48 110.22 -3.46 0.667 12.110 11.964 1.21 
7 1.5 12.90 11.36 12.64 24 1.546 1.507 2.55 
a Expressed as [(initial conc.−re–assay conc.)/average]×100%. 
 
CONCLUSION 
In ultimate analysis, it can be vouchsafed that, we have developed 
and validated a sensitive, selective and rapid LC–MS/MS method in 
MRM mode for the simultaneous determination of AS and AQ in 
human plasma. The method utilizes deuterated standards as internal 
standards for quantification. Hence, possible matrix effect related 
problems are eliminated effectively. Additionally, sample 
preparation using SPE method with direct injection (no drying and 
reconstitution) gave consistent and reproducible recoveries for the 
analytes from the human plasma. The stability of AS and AQ in 
plasma and in aqueous samples under different conditions has been 
extensively evaluated and the results met the acceptance criteria as 
per recent FDA guidelines. The method showed suitability for 
clinical studies in humans. In addition, assay reproducibility is 
effectively proved by incurred sample reanalysis. 
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